10/16/2024 | Press release | Distributed by Public on 10/16/2024 14:36
| | |
Per Share
|
| |
Total
|
| ||||||
Public offering price
|
| | | $ | | | | | $ | | | ||
Underwriting discount and commission(1)
|
| | | $ | | | | | $ | | | ||
Proceeds, before expenses, to us
|
| | | $ | | | | | $ | | | |
| | |
Page
|
| |||
About This Prospectus Supplement
|
| | | | S-1 | | |
Cautionary Note Regarding Forward-Looking Statements and Industry Data
|
| | | | S-3 | | |
Where You Can Find More Information
|
| | | | S-5 | | |
Information Incorporated by Reference
|
| | | | S-5 | | |
Summary
|
| | | | S-7 | | |
The Offering
|
| | | | S-9 | | |
Risk Factors
|
| | | | S-10 | | |
Use of Proceeds
|
| | | | S-12 | | |
Dilution
|
| | | | S-13 | | |
Underwriting
|
| | | | S-14 | | |
Legal Matters
|
| | | | S-20 | | |
Experts
|
| | | | S-20 | | |
|
Summary
|
| | | | 2 | | |
|
Risk Factors
|
| | | | 3 | | |
|
Special Note Regarding Forward-Looking Statements
|
| | | | 4 | | |
|
Use of Proceeds
|
| | | | 5 | | |
|
Description of Capital Stock
|
| | | | 6 | | |
|
Description of Debt Securities
|
| | | | 9 | | |
|
Description of Warrants
|
| | | | 16 | | |
|
Description of Units
|
| | | | 19 | | |
|
Legal Ownership of Securities
|
| | | | 20 | | |
|
Plan of Distribution
|
| | | | 23 | | |
|
Legal Matters
|
| | | | 26 | | |
|
Experts
|
| | | | 26 | | |
|
Where You Can Find More Information
|
| | | | 26 | | |
|
Information Incorporated by Reference
|
| | | | 26 | | |
|
Public offering price per share of common stock
|
| | | | | | | | | $ | | | |
|
Net tangible book value per share as of June 30, 2024
|
| | | $ | 0.36 | | | | | | | | |
|
Increase in net tangible book value per share attributable to the offering
|
| | | $ | | | | | | | | | |
|
As adjusted net tangible book value per share after this offering
|
| | | | | | | | | $ | | | |
|
Dilution per share to investors participating in this offering
|
| | | | | | | | | $ | | | |
Underwriter
|
| |
Number of Shares
|
|
Piper Sandler & Co.
|
| | | |
Oppenheimer & Co. Inc.
|
| | | |
Total
|
| | | |
| | |
Per Share
|
| |
Without
Option |
| |
With
Option |
| |||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | |||
Underwriting discount and commissions payable by us
|
| | | $ | | | | | $ | | | | | $ | | | |||
Proceeds to Capricor Therapeutics, Inc., before expenses
|
| | | $ | | | | | $ | | | | | $ | | | |
|
SUMMARY
|
| | | | 2 | | |
|
RISK FACTORS
|
| | | | 3 | | |
|
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | 4 | | |
|
USE OF PROCEEDS
|
| | | | 5 | | |
|
DESCRIPTION OF CAPITAL STOCK
|
| | | | 6 | | |
|
DESCRIPTION OF DEBT SECURITIES
|
| | | | 9 | | |
|
DESCRIPTION OF WARRANTS
|
| | | | 16 | | |
|
DESCRIPTION OF UNITS
|
| | | | 19 | | |
|
LEGAL OWNERSHIP OF SECURITIES
|
| | | | 20 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 23 | | |
|
LEGAL MATTERS
|
| | | | 26 | | |
|
EXPERTS
|
| | | | 26 | | |
|
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 26 | | |
|
INFORMATION INCORPORATED BY REFERENCE
|
| | | | 26 | | |